-
PDF
- Split View
-
Views
-
Cite
Cite
Correction to: Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy, European Heart Journal, Volume 45, Issue 40, 21 October 2024, Page 4314, https://doi.org/10.1093/eurheartj/ehae594
Close - Share Icon Share
This is a correction to: Daniel Gaudet, Susanne Greber-Platzer, Laurens F. Reeskamp, Gabriella Iannuzzo, Robert S. Rosenson, Samir Saheb, Claudia Stefanutti, Erik Stroes, Albert Wiegman, Traci Turner, Shazia Ali, Poulabi Banerjee, Tiera Drewery, Jennifer McGinniss, Alpana Waldron, Richard T. George, Xue-Qiao Zhao, Robert Pordy, Jian Zhao, Eric Bruckert, and Frederick J. Raal, Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy, European Heart Journal, Volume 45, Issue 27, 14 July 2024, Pages 2422–2434, https://doi.org/10.1093/eurheartj/ehae325
The originally published version of this manuscript contained the following sentence: “Recent European Society of Cardiology and European Atherosclerosis Society guidelines for patients with HoFH recommend LDL-C levels of <2.5 mmol/L (<100 mg/dL) and <1.8 mmol/L (<70 mg/dL) for adults with and without ASCVD, respectively.” This has been corrected online to: “Recent European Society of Cardiology and European Atherosclerosis Society guidelines for patients with HoFH recommend LDL-C levels of <1.8 mmol/L (<70 mg/dL) and <1.4 mmol/L (<55 mg/dL) for adults with and without ASCVD, respectively.”
On 16 December 2024 this correction notice was amended to correct the inadvertent transposition of the LDL-C levels in the original article correction. The corrected sentence was amended from:
“Recent European Society of Cardiology and European Atherosclerosis Society guidelines for patients with HoFH recommend LDL-C levels of <1.8 mmol/L (<70 mg/dL) and <1.4 mmol/L (<55 mg/dL) for adults with and without ASCVD, respectively.”
to:
“Recent European Society of Cardiology and European Atherosclerosis Society guidelines for patients with HoFH recommend LDL-C levels of <1.4 mmol/L (<55 mg/dL) and <1.8 mmol/L (<70 mg/dL) for adults with and without ASCVD, respectively.”
The transposition has also been corrected in article https://doi.org/10.1093/eurheartj/ehae325.
